Novo Nordisk AS (NVO) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $0.96 (est. $0.81) — inline Revenue: $12.21B (est. $11.35B) — inline Reported: 2026-08-04 Recent Quarters Q1 FY26 (2026-05-06): EPS $1.04 vs est $0.87 · Rev $15.17B vs est $11.13B Q4 FY25 (2026-02-04): EPS $1.00 vs est $0.89 · Rev $12.34B vs est $12.08B Q3 FY25 (2025-11-05): EPS $1.03 vs est $0.77 · Rev $11.74B vs est $11.88B Q2 FY25 (2025-08-06): EPS $0.91 vs est $0.93 · Rev $11.68B vs est $11.79B About Novo Nordisk AS With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemo...